Evaluation of corneal endothelial cell morphology off and on treatment by specular microscopy in children and adolescents with attention deficit hyperactivity disorder

被引:0
|
作者
Koc, Hakan [1 ,4 ]
Onal, Bedia Sultan [2 ]
Hosoglu, Esra [3 ]
机构
[1] Giresun Univ, Dept Ophthalmol, Giresun, Turkiye
[2] Giresun Univ, Dept Child & Adolescent Psychiat, Giresun, Turkiye
[3] Karadeniz Tech Univ, Dept Child & Adolescent Psychiat, Trabzon, Turkiye
[4] Giresun Univ, Fac Med, Dept Ophthalmol Giresun, Mehmet Izmen St 145, TR-28100 Giresun, Turkiye
关键词
Attention deficit hyperactivity disorder; cornea endothelium; speculer microscopy; DEFICIT/HYPERACTIVITY DISORDER;
D O I
10.1080/15569527.2024.2303442
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose To determine the structure and properties of corneal endothelial cells in children and adolescents with ADHD who received methylphenidate treatment at least six months.Method The prospective, observational study included 33 eyes of 33 patients diagnosed with ADHD who received methylphenidate treatment for at least six months, 33 eyes of 33 patients newly diagnosed with ADHD who did not start medication treatment, and 33 eyes of 33 healthy individuals. Average cell density, coefficient of variation, maximum cell area, normal cell area, minimum cell area, average cell area, and hexagonality ratio values were evaluated by non-contact specular microscopy. The parameters recorded in all three groups were compared.Results The average age of children in the ADHD + MPH, ADHD, and control groups is 9 +/- 1.7, 8.9 +/- 2.3, and 8.9 +/- 1.8 years, respectively. (p > 0.05) The average MPH treatment dose is 0.94 +/- 0.19 mg/kg, the average daily MPH intake is 34.12 +/- 14.04 mg, and the average duration of use of MPH is 24.03 +/- 12.46 months. Central corneal thickness (CCT) was measured as an average of 540.45 +/- 31.23 in the ADHD + MPH group, 540.61 +/- 29.69 in the ADHD group, and 546.58 +/- 27.72 in the control group. (p = 0.499) The average coefficient of variation (CV) values were measured as 25.48 +/- 4.22 in the ADHD + MPH group, 26.12 +/- 3.48 in the ADHD group, and 26.12 +/- 3.64 in the control group. (p = 0.491) The average hexagonality ratio (%) (HEX) values were measured as 69.45 +/- 8.41 in the ADHD + MPH group, 68.21 +/- 6.82 in the ADHD group, and 68.91 +/- 7.97 in the control group. (p = 0.892) No statistically significant difference was observed between all three groups in terms of all parameters.Conclusion Methylphenidate treatment administered for at least six months with a diagnosis of ADHD did not have a toxic effect on the corneal endothelium.
引用
收藏
页码:120 / 123
页数:4
相关论文
共 50 条
  • [1] Corneal endothelial morphology and thickness changes in children with attention-deficit hyperactivity disorder
    Kalinli, E. M.
    Aydemir, E.
    Aydemir, G. Aksoy
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2021, 53 : S236 - S236
  • [2] Guanfacine for the treatment of attention deficit hyperactivity disorder in children and adolescents
    Rizzo, Renata
    Martino, Davide
    [J]. EXPERT REVIEW OF NEUROTHERAPEUTICS, 2015, 15 (04) : 347 - 354
  • [3] Attention deficit hyperactivity disorder in children and adolescents
    Flisher, A. J.
    Hawkridge, S.
    [J]. SOUTH AFRICAN JOURNAL OF PSYCHIATRY, 2013, 19 (03) : 136 - 140
  • [4] Treatment of attention deficit hyperactivity disorder in children and adolescents - Safety considerations
    Wolraich, Mark L.
    McGuinn, Laura
    Doffing, Melissa
    [J]. DRUG SAFETY, 2007, 30 (01) : 17 - 26
  • [5] Transcranial micropolarization in treatment of attention deficit hyperactivity disorder in children and adolescents
    Kropotov, YD
    Chutko, LS
    Yakovenko, VA
    Grin-Yatsenko, VA
    [J]. ZHURNAL NEVROPATOLOGII I PSIKHIATRII IMENI S S KORSAKOVA, 2002, 102 (05): : 26 - 28
  • [6] Practitioner characteristics and the treatment of children and adolescents with attention deficit hyperactivity disorder
    Mitchell, Philip B.
    Levy, Florence
    Hadzi-Pavlovic, Dusan
    Concannon, Patrick E.
    Hutchins, Paul
    Mulcahy, Desmond L.
    Clarke, Simon D.
    Salmelainen, Pia A.
    Warner, Alexandra
    Hughes, Clifford F.
    [J]. JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2012, 48 (06) : 483 - 489
  • [7] Clinical guidelines for the treatment of attention deficit hyperactivity disorder in children and adolescents
    Ulloa, RE
    Arroyo, E
    Avila, JM
    Cárdenas, JA
    Cruz, E
    Gómez, D
    Higuera, F
    Rivera, F
    Santos, G
    Velásquez, V
    de la Peña, F
    [J]. SALUD MENTAL, 2005, 28 (05) : 1 - 10
  • [8] Lisdexamfetamine in the treatment of adolescents and children with attention-deficit/hyperactivity disorder
    Najib, Jadwiga
    [J]. ADOLESCENT HEALTH MEDICINE AND THERAPEUTICS, 2012, 3 : 51 - 66
  • [9] Efficacy of atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder
    Dunn, D
    Allen, A
    Thomason, C
    Zhang, S
    Michelson, D
    Kelsey, D
    [J]. ANNALS OF NEUROLOGY, 2003, 54 : S143 - S143
  • [10] Diagnosis and treatment of children and adolescents with attention-deficit/hyperactivity disorder
    Brown, MB
    [J]. JOURNAL OF COUNSELING AND DEVELOPMENT, 2000, 78 (02): : 195 - 203